Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by GENFIT S.A. GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval September 23, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update September 19, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis July 26, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH June 17, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis June 10, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT to Present Latest ACLF Research at EASL Congress™ 2024 May 29, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT: May 22, 2024 Combined Shareholders Meeting Results May 22, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT Reports First Quarter 2024 Financial Information May 14, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023) April 25, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents April 15, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F April 05, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update April 04, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT Announces Revenues and Cash Position as of December 31, 2023 February 29, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT Announces 2024 Financial Calendar January 15, 2024 From GENFIT S.A. Via GlobeNewswire GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC) December 08, 2023 From GENFIT S.A. Via GlobeNewswire Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC December 07, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials December 06, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023 November 16, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine November 13, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT Reports Third Quarter 2023 Financial Information November 09, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023 November 02, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology September 26, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update September 20, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT to Participate in Upcoming Investor Conferences September 05, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications August 10, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023 June 07, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset May 31, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT: May 24, 2023 Combined Shareholders Meeting results May 24, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology May 23, 2023 From GENFIT S.A. Via GlobeNewswire GENFIT Reports First Quarter 2023 Financial Information May 11, 2023 From GENFIT S.A. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.